Choroidal melanoma treatment continues to show encouraging results at 9 months

Source: Healio, March 2023

Belzupacap sarotalocan via suprachoroidal administration demonstrated positive interim phase 2 safety and efficacy data at an average of 9 months follow-up for the treatment of early-stage choroidal melanoma.

In the ongoing trial, belzupacap sarotalocan (bel-sar), also known as AU-011, is being evaluated for tumor control and visual acuity preservation after up to three cycles of treatment by single and multiple ascending doses, according to a press release from Aura Biosciences. Twenty patients have been enrolled in the trial, and in cohorts 5 and 6, there was a statistically significant reduction of –0.289 mm per year in tumor growth rate (P .0001) compared with each patient’s documented growth rate at entry and a 100% tumor control rate.

Additionally, the visual acuity preservation rate was 88% in cohorts 5 and 6, with most patients considered as high risk for vision loss.
READ THE ORIGINAL FULL ARTICLE